Jubilant Pharmova Ltd (JUBLPHARMA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Acutaas Chemical

Granules India

Sai Life

Natco Pharma

Neuland Labs.

ERIS Lifescience

Caplin Point Lab

Alembic Pharma

Cohance Life

Jubilant Pharmo

OneSource Speci.

Why is Jubilant Pharmova Ltd ?

Poor long term growth as Operating profit has grown by an annual rate -6.55% of over the last 5 years

Negative results in Dec 25

PAT(Q) At Rs 79.62 cr has Fallen at -31.1%
OPERATING PROFIT TO INTEREST (Q) Lowest at 5.16 times
CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 623.20 cr

Underperformed the market in the last 1 year

Even though the market (BSE500) has generated returns of 7.71% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -10.52% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Jubilant Pharmo for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Jubilant Pharmo

-10.52%

-0.29

36.48%

Sensex

7.07%

0.61

11.53%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

0.80%

EBIT Growth (5y)

-8.16%

EBIT to Interest (avg)

3.32

Debt to EBITDA (avg)

3.16

Net Debt to Equity (avg)

0.34

Sales to Capital Employed (avg)

0.77

Tax Ratio

33.32%

Dividend Payout Ratio

102.46%

Pledged Shares

5.40%

Institutional Holding

27.18%

ROCE (avg)

9.12%

ROE (avg)

6.76%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.26

EV to EBIT

20.22

EV to EBITDA

13.53

EV to Capital Employed

1.94

EV to Sales

2.16

PEG Ratio

6.02

Dividend Yield

0.54%

ROCE (Latest)

9.88%

ROE (Latest)

7.56%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

ROCE(HY)

Highest at 9.68%

DEBT-EQUITY RATIO(HY)

Lowest at 0.44 times

NET SALES(Q)

Highest at Rs 2,122.50 cr

-12What is not working for the Company

PAT(Q)

At Rs 79.62 cr has Fallen at -31.1%

OPERATING PROFIT TO INTEREST (Q)

Lowest at 5.16 times

CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 623.20 cr

INTEREST(Q)

Highest at Rs 56.10 cr

PBT LESS OI(Q)

Lowest at Rs 112.60 cr.

EPS(Q)

Lowest at Rs 3.54

Loading Valuation Snapshot...

Here's what is working for Jubilant Pharmo

Net Sales - Quarterly

Highest at Rs 2,122.50 cr

in the last five quarters

MOJO Watch

Near term sales trend is positive

Net Sales (Rs Cr)

Debt-Equity Ratio - Half Yearly

Lowest at 0.44 times

in the last five half yearly periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Jubilant Pharmo

Profit After Tax (PAT) - Quarterly

At Rs 79.62 cr has Fallen at -31.1%

Year on Year (YoY)

MOJO Watch

Near term PAT trend is very negative

PAT (Rs Cr)

Operating Profit to Interest - Quarterly

Lowest at 5.16 times

in the last five quarters

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 112.60 cr has Fallen at -19.69%

Year on Year (YoY)

MOJO Watch

Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Interest - Quarterly

Highest at Rs 56.10 cr

in the last five quarters and Increased by 11.75 % (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Profit Before Tax less Other Income (PBT) - Quarterly

Lowest at Rs 112.60 cr.

in the last five quarters

MOJO Watch

Near term PBT trend is negative

PBT less Other Income (Rs Cr)

Earnings per Share (EPS) - Quarterly

Lowest at Rs 3.54

in the last five quarters

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (Rs)

Cash and Cash Equivalents - Half Yearly

Lowest at Rs 623.20 cr

in the last six half yearly periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Non Operating Income - Quarterly

Highest at Rs 20.50 cr

in the last five quarters

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating Income